CD38 and leukemia: To further investigate the strength of our adoptive immunotherapy, we sought to evaluate whether CAR.CD123-NK cells were able to recognize and eliminate CD34+CD38− AML cells, which are known to represent the leukaemia-initiating cell compartment characterized by high resistance to chemotherapy [35].